Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 153749-89-4 | MDL No. : | MFCD01861221 |
Formula : | C11H18N2O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | LKAJZBMOVZIKHA-UHFFFAOYSA-N |
M.W : | 210.27 | Pubchem ID : | 2756784 |
Synonyms : |
|
Num. heavy atoms : | 15 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.82 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 61.15 |
TPSA : | 53.33 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.32 cm/s |
Log Po/w (iLOGP) : | 2.53 |
Log Po/w (XLOGP3) : | 1.78 |
Log Po/w (WLOGP) : | 1.92 |
Log Po/w (MLOGP) : | 1.05 |
Log Po/w (SILICOS-IT) : | 1.06 |
Consensus Log Po/w : | 1.67 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.07 |
Solubility : | 1.8 mg/ml ; 0.00857 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.52 |
Solubility : | 0.638 mg/ml ; 0.00303 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -1.37 |
Solubility : | 9.05 mg/ml ; 0.0431 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.74 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280 | UN#: | N/A |
Hazard Statements: | H302-H317 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
97% | With pyridine; oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane; acetonitrile at -5 - 20℃; | Acetonitrile (220 mL) and DMF (3.82 mL, 49.4 mmol) were added to a 500 mL round bottom flask equipped with stir bar. Cooled the mixture down to-5°C and to it added oxalyl chloride (24.7 mL, 49.4 mmol, 2 M dichloromethane). The resulting mixture was stirred for 15 min. This was followed by addition of solution of 2-carbamoyl-piperidine-1- carboxylic acid tert-butyl ester (9.4 g, 41.2 mmol) in acetonitrile. (50 mL) and pyridine (8.3 mL, 103 mmol). Reaction mixture was left stirring at room temperature overnight. The reaction mixture was concentrated in vacuo and the residue was dissolved in ethyl acetate (300 mL). The organic phase was successively washed with water (300 mL) and brine (200 mL), dried (sodium sulfate), filtered and concentrated in vacuo to isolate the title compound (8.44 g, 97percent) as a yellow solid. 1H NMR (CDCIs), 8 (ppm): 5.23 (bs, 1H), 4.03 (bs, 1H), 2.93 (t, 1H), 1.75 (m, 5H), 1.46 (m, 10H). |
97% | Stage #1: With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane; acetonitrile at -5℃; for 0.25 h; Stage #2: With pyridine In dichloromethane; acetonitrile at 20℃; |
Piperidine-1, 2-dicarboxylic acid-1-tert-butyl ester (12.8 g, 55.6 mmol) and THF (170 mL) were added to a 500 mL round bottom flask equipped with stir bar. The solution was cooled to-20°C and triethylamine (10.1 mL, 72.3 mmol) was added followed by ethyl [CHLOROFORMATE] (5.32 mL, 55.6 [MMOL).] The resulting white precipitate was left stirring at- [10°C] for 1 h. Aqueous ammonia (22.6 mL, 1168 mmol) was added to the above reaction mixture and the clear reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and the isolated residue was dissolved in ethyl acetate (300 [ML).] The organic phase was successively washed with water (300 mL) and brine (200 mL), dried (sodium sulfate), filtered and concentrated in vacuo to isolate a clear gum. The gum was triturated with hexanes to isolate the title compound (9.4 g, [74percent)] as a white [SOLID. LH-NMR (CDC13), 6] (ppm): 6.03 (bs, 1H), 5.55 (bs, 1H), 4.77 (bs, 1H), 4.05 (bs, 1H), 2.81 (t, 1H), 2.27 (bs, 1H), 1.47 (m, 14H). Acetonitrile (220 mL) and DMF (3.82 mL, 49.4 mmol) were added to a 500 [ML] round bottom flask equipped with stir bar. Cooled the mixture down to-5°C and to it added oxalyl chloride (24.7 mL, 49.4 mmol, 2 M dichloromethane). The resulting mixture was stirred for 15 min. This was followed by addition of solution of 2-carbamoyl-piperidine-1- carboxylic acid tert-butyl ester (9.4 g, 41.2 mmol) in acetonitrile (50 [ML)] and pyridine (8.3 mL, 103 [MMOL).] Reaction mixture was left stirring at room temperature overnight. The reaction mixture was concentrated in vacuo and the residue was dissolved in ethyl acetate (300 mL). The organic phase was successively washed with water (300 [ML)] and brine (200 mL), dried (sodium sulfate), filtered and concentrated in vacuo to isolate the title compound (8.44 g, 97percent) as a yellow [SOLID. LH-NMR (CDC13), 6 (PPM)] : 5.23 (bs, 1H), 4.03 (bs, 1H), 2.93 (t, 1H), 1.75 (m, [5H),] 1.46 (m, 10H). |
[ 144688-70-0 ]
tert-Butyl 2-cyanopyrrolidine-1-carboxylate
Similarity: 0.96
[ 228244-04-0 ]
(S)-tert-Butyl 2-cyanopyrrolidine-1-carboxylate
Similarity: 0.96
[ 142253-50-7 ]
(S)-tert-Butyl 2-(cyanomethyl)pyrrolidine-1-carboxylate
Similarity: 0.89
[ 256411-39-9 ]
1-Boc-4-(Cyanomethyl)piperidine
Similarity: 0.89
[ 91419-52-2 ]
tert-Butyl 4-cyanopiperidine-1-carboxylate
Similarity: 0.87
[ 144688-70-0 ]
tert-Butyl 2-cyanopyrrolidine-1-carboxylate
Similarity: 0.96
[ 228244-04-0 ]
(S)-tert-Butyl 2-cyanopyrrolidine-1-carboxylate
Similarity: 0.96
[ 142253-50-7 ]
(S)-tert-Butyl 2-(cyanomethyl)pyrrolidine-1-carboxylate
Similarity: 0.89
[ 256411-39-9 ]
1-Boc-4-(Cyanomethyl)piperidine
Similarity: 0.89
[ 91419-52-2 ]
tert-Butyl 4-cyanopiperidine-1-carboxylate
Similarity: 0.87
[ 144688-70-0 ]
tert-Butyl 2-cyanopyrrolidine-1-carboxylate
Similarity: 0.96
[ 256411-39-9 ]
1-Boc-4-(Cyanomethyl)piperidine
Similarity: 0.89
[ 91419-52-2 ]
tert-Butyl 4-cyanopiperidine-1-carboxylate
Similarity: 0.87
[ 483366-12-7 ]
(2S,4R)-tert-Butyl 2-cyano-4-hydroxypyrrolidine-1-carboxylate
Similarity: 0.87
[ 301225-58-1 ]
tert-Butyl 4-(propylamino)piperidine-1-carboxylate
Similarity: 0.85
[ 256411-39-9 ]
1-Boc-4-(Cyanomethyl)piperidine
Similarity: 0.89
[ 91419-52-2 ]
tert-Butyl 4-cyanopiperidine-1-carboxylate
Similarity: 0.87
[ 301225-58-1 ]
tert-Butyl 4-(propylamino)piperidine-1-carboxylate
Similarity: 0.85
[ 108612-54-0 ]
tert-Butyl methyl(piperidin-4-yl)carbamate
Similarity: 0.85
[ 534595-51-2 ]
1-Boc-4-(isopropylamino)piperidine
Similarity: 0.85